title: New scaffold for recombinant human bone morphogenetic protein-2.
abstract: A bioactive and resorbable scaffold is necessary to exhibit the osteoinductive potency of recombinant human bone morphogenetic protein-2 (rhBMP-2). In a previous study, we found that synthetic octacalcium phosphate (OCP) enhances bone regeneration and is replaced by newly formed bone after it is resorbed. We hypothesized that OCP may be useful as an effective scaffold for rhBMP-2 to enhance bone regeneration. To test this hypothesis, the present study was designed to investigate whether an OCP/BMP composite implant could more effectively enhance bone regeneration. A critical-sized defect was made in a rat calvarium and 1. 15 mg of OCP combined with 10 microg of rhBMP-2 (OCP/BMP 10 microg), 2. 15 mg of OCP combined with 1 microg of rhBMP-2 (OCP/BMP 1 microg), or 3. OCP (OCP alone) was implanted into the defect and fixed at 4 or 8 weeks after implantation. The percentage of newly formed bone (n-Bone%) in the defect was determined by a histomorphometrical analysis. A statistical analysis showed that n-Bone% with OCP/BMP was significantly higher than that with OCP at both time points, whereas the difference in n-Bone% between OCP/BMP 10 microg and OCP/BMP 1 microg was not significant. The present results suggest that OCP can be used as an effective scaffold for rhBMP-2 and this OCP delivery system may be able to reduce the standard effective dose of rhBMP-2, which would be beneficial because low doses (<100 microg/g OCP) of rhBMP-2 enhance bone regeneration.
authors.affiliation: Division of Clinical Cell Therapy, Department of Translational Research, Center for Translational and Advanced Animal Research, Tohoku University School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai 980-8574, Japan. kamakura@mail.tains.tohoku.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Kamakura
authors.forename: S
authors.initials: S
authors.lastname: Nakajo
authors.forename: O
authors.initials: O
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Sasano
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects; D002130:Calcium Phosphates / Q000378:metabolism; D006801:Humans; D008297:Male; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012886:Skull / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C022045:octacalcium phosphate